- Home
- DOUG vs HURA Comparison
DOUG vs HURA Comparison
Compare DOUG & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DOUG | HURA |
|---|---|---|
| Founded | 1911 | 2009 |
| Country | United States | United States |
| Employees | 580 | N/A |
| Industry | Building operators | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.4M | 160.5M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | DOUG | HURA |
|---|---|---|
| Price | $1.53 | $2.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | ★ 446.7K | 170.1K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.68 | 47.93 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $955,578,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.52 | $0.41 |
| 52 Week High | $3.10 | $3.43 |
Technical Indicators
Market Signals| Indicator | DOUG | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 29.76 | 45.18 |
| Support Level | $1.55 | $1.89 |
| Resistance Level | $1.82 | $2.24 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 10.00 | 25.00 |
Price Performance
Historical ComparisonAbout DOUG Douglas Elliman Inc.
Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.